In the Claims:

The following listing of claims will replace any/all prior versions, and listings, of claims in the application:

Claim **1** (Currently Amended) A method of ~~selectively inhibiting reuptake of norepinephrine~~ treating an individual suffering from peripheral neuropathy, the method comprising the step of administering to the individual a therapeutically effective amount of a composition ~~to an individual, the composition~~ comprising a compound having a pharmacological selectivity of serotonin (K_i)/norepinephrine (K_i) of at least about 5000.

Claim **2** (Original) The method of claim **1** wherein said composition is administered in an amount of about 0.1 to about 10 mg/day.

Claim **3** (Original) The method of claim **2** wherein said composition is administered in an amount of about 0.5 to about 8 mg/day.

Claim **4** (Original) The method of claim **3** wherein said composition is administered in an amount of about 0.5 to about 5 mg/day.

Claim **5** (Original) The method of claim **4** wherein said composition is administered in an amount of about 0.5 to about 2.5 mg/day.

Claim **6** (Original) The method of claim **5** wherein said composition is administered in an amount of about 0.5 to about 0.9 mg/day.

Claim **7** (Original) The method of claim **6** wherein said composition is administered in an amount of about 0.5 to about 0.8 mg/day.

Claim **8** (Original) The method of claim **7** wherein said composition is administered in an amount of about 0.5 to about 0.75 mg/day.

Claim **9** (Original) The method of claim **1** wherein said composition is administered orally, topically, parenterally, transdermally, rectally, or vaginally.

Claim **10** (Original) The method of claim **9** wherein said composition is orally administered, and further comprising a pharmaceutically acceptable carrier selected from the group consisting of a binder, diluent, lubricant, disintegrating agent, effervescing agent, dyestuff, sweetener, wetting agent, and mixtures thereof.

Claim **11** (Original) The method of claim **10** wherein the oral administration is by a sachet, capsule, tablet, or aerosol spray.

Claim **12** (Original) The method of claim **9** wherein said composition is parenterally administered subcutaneously, intraveously, or intramuscularly.

Claim **13** (Original) The method of claim **1** wherein said compound comprises an optically pure (S,S) reboxetine, or a pharmaceutically acceptable salt thereof, said compound being substantially free of (R,R) reboxetine.

Claim **14** (Original) The method of claim **13** wherein the pharmaceutically acceptable salt is a methanesulfonate salt.

Claim **15** (Original) The method of claim **13** wherein the optically pure (S,S) reboxetine or pharmaceutically acceptable salt thereof comprises at least about 90 wt.% of (S,S) reboxetine, and less than about 10 wt.% of (R,R) reboxetine, based on the total weight of the (S,S) and (R,R) reboxetine present.

Claim **16** (Original) The method of claim **15** wherein the optically pure (S,S) reboxetine or pharmaceutically acceptable salt thereof comprises at least about 97 wt.% of (S,S) reboxetine and less than about 3 wt.% of (R,R) reboxetine, based on the total weight of the (S,S) and (R,R) reboxetine present.

Claim **17** (Original) The method of claim **16** wherein the optically pure (S,S) reboxetine or pharmaceutically acceptable salt thereof comprises at least about 99 wt.% of (S,S) reboxetine and less than about 1 wt.% of (R,R) reboxetine, based on the total weight of the (S,S) and (R,R) reboxetine present.

Claims **18-31** (Cancelled).

Claim **32** (Original) The method of claim **1** wherein the compound has a pharmacological selectivity of serotonin (K_i)/norepinephrine (K_i) of at least about 10,000.

Claim **33** (Original) The method of claim **32** wherein the compound has a pharmacological selectivity of serotonin (K_i)/norepinephrine (K_i) of at least about 12,000.

Claim **34** (Original) The method of claim **33** wherein the compound has a pharmacological selectivity of serotonin (K_i)/norepinephrine (K_i) of at least about 25,000.

Claim **35** (Original) The method of claim **34** wherein the compound has a pharmacological selectivity of serotonin (K_i)/norepinephrine (K_i) of at least about 50,000.

Claim **36** (Original) The method of claim **35** wherein the compound has a pharmacological selectivity of serotonin (K_i)/norepinephrine (K_i) of at least about 75,000.

Claim **37** (Original) The method of claim **36** wherein the compound has a pharmacological selectivity of serotonin (K_i)/norepinephrine (K_i) of at least about 100,000.

Claim **38** (Currently Amended) A method of ~~treating a human suffering from a condition, or preventing said condition, wherein inhibiting reuptake of norepinephrine provides a benefit,~~ preventing an individual from having peripheral neuropathy, the method comprising the step of administering to the individual a therapeutically effective amount of a composition comprising a compound having a pharmacological selectivity of serotonin (K_i)/norepinephrine (K_i) of at least about 5000.

Claim **39** (Currently Amended) A method of treating ~~a human suffering from a condition, or preventing said condition, wherein inhibiting reuptake of norepinephrine provides a benefit,~~ an individual suffering from peripheral neuropathy while diminishing adverse side effects, the method comprising the step of administering to the individual a total dose of about 0.1 to about 10 mg/day of an optically pure (S,S) reboxetine, or a pharmaceutically acceptable salt thereof, ~~to an individual,~~ said optically pure (S,S) reboxetine being substantially free of (R,R) reboxetine.

Claim **40** (Original) The method of claim **39** wherein said adverse side effects comprise dizziness, insomnia, lightheadedness, changes in blood pressure, sweating, gastrointestinal disturbances, sexual dysfunction in males, anticholinergic-like effects, and side effects with drug-drug interactions.

Claims **41-53** (Canceled).